Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
Combination Shows Promise in Post-Osimertinib Lung Cancer Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance Jun 06, 2021
Novel CDK 4/6 Inhibitor Proves Mettle in HR+/HER2- Advanced Breast Cancer Dalpiciclib may be a new treatment option; palbociclib and ribociclib continue to shine Jun 06, 2021
Perioperative Chemo Enough in Esophageal Cancer? MAGIC/FLOT regimens yielded similar overall survival to multimodal CROSS regimen Jun 06, 2021
CAR-T Drives High Response in Relapsed/Refractory ALL ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit Jun 06, 2021
Antibody-Drug Conjugate Active in Resistant Lung Cancer Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan Jun 05, 2021
Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone Jun 05, 2021
Combination Therapy Achieves High Response in Ph+ ALL Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease Jun 05, 2021
Small PFS Bump in Synovial Sarcoma With Novel Drug But questions raised over control arm and whether improvement represents a meaningful benefit Jun 05, 2021
Radioligand Therapy Boosts Survival in Metastatic CRPC PSMA-directed agent improved overall survival by median 4 months Jun 04, 2021
Adding Chemo to Standard Care No Help for Cervical Cancer Similar OS, PFS, and patterns of recurrence, with more toxicity Jun 04, 2021
PD-1 Inhibitor Shows Benefit in Nasopharyngeal Cancer Toripalimab plus first-line chemo improved survival in recurrent/metastatic disease Jun 03, 2021
Olaparib Wins in Early BRCA-Mutant Breast Cancer First trial to show adjuvant PARP inhibitor benefit inBRCA mutation carriers Jun 03, 2021
Survival Boost With First-Line Immunotherapy for Esophageal Cancer Nivolumab plus ipilimumab or chemo offers new option for advanced, metastatic disease Jun 03, 2021
'A Quantum Leap Forward': Potential New Standard in High-Risk RCC Adjuvant immunotherapy led to 32% reduction in the risk of recurrence, positive trend in OS Jun 03, 2021
Vaccination, Screening Succeeds in Cervical and Prostate Cancers Cervical cancer rates on the decline; PSA testing benefits younger Black men May 19, 2021
PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancer Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo May 19, 2021
Novel Immunotherapy Boosts Melanoma Outcomes Adding LAG-3 checkpoint inhibitor to nivolumab extended PFS in patients with advanced disease May 19, 2021
High Marks for CAR T Cells in R/R Myeloma Response rates of 70-100% with BCMA-targeted products for heavily treated disease Jun 03, 2020
Second Surgery Gets OS Win in Recurrent Ovarian Cancer Survival improved by nearly 8 months with cytoreductive surgery at first relapse Jun 02, 2020
Early Palliation: Boon for AML Patients on Intensive Chemo Intervention led to marked improvements in QoL, mental distress, end-of-life care Jun 02, 2020
Pembrolizumab May Help in Triple-Negative Breast Cancer Upfront therapy extends progression-free survival in metastatic disease, study shows Jun 01, 2020
Surgery for Metastatic Breast Cancer Fails to Boost Overall Survival Cumulative data, though, don't rule out benefit for selected patients with de novo stage IV disease Jun 01, 2020
Add-On Tucatinib Ups Survival in Breast Cancer With Brain Mets TKI plus trastuzumab-capecitabine reduced risk of death by nearly half Jun 01, 2020
VRd Still Reigns in Newly Diagnosed Myeloma KRd fails to prove superiority in head-to-head trial Jun 01, 2020
CAR T-Cell Therapy Impresses in Indolent NHL Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting May 31, 2020
Oral ADT Slashes Heart Risk in Advanced Prostate Cancer Novel GnRH antagonist has potential to be new standard, says researcher May 30, 2020
Sentinel Node Biopsy Proves Mettle in H&N Cancer Senti-MER study results establish SN biopsy as standard of care, researcher says May 30, 2020
Studies Make Case for Hormonal Therapy in nmCRPC Prolonged survival with three different androgen signaling inhibitors May 30, 2020
HCQ Linked to Harm in Cancer Patients Combination with azithromycin associated with three-fold risk of mortality, registry study shows May 28, 2020
New First-Line Standard in Metastatic Bladder Cancer "High bar to beat" as avelumab maintenance improves median survival by over 7 months May 28, 2020
Paradigm Shift Coming for Early NSCLC? Postoperative osimertinib doubles DFS in patients with stages Ib-IIIa EGFR+ lung cancer May 28, 2020
CAR T Cells Show Activity in Solid Tumors High response rate in mesothelioma, shrinkage of gastric, pancreatic tumors Jun 07, 2019
Keytruda 'Switch' Extends PFS in Advanced Bladder Cancer Matthew Galsky, MD, discusses possible role of maintenance PD-1 blockade Jun 06, 2019
Jury Out on Margetuximab in Advanced HER2+ Breast Cancer One-month PFS boost, but certain subgroups may derive more benefit Jun 05, 2019
Depth of Tumor Response a Better Survival Predictor Could improve on RECIST as outcome measure in oncology Jun 05, 2019
Preop Chemo Reduces CRC Surgical Morbidity Lower 2-year recurrence rate versus adjuvant therapy but not significantly Jun 04, 2019
Good News Continues for Enfortumab Vedotin in Bladder Ca Phase II trial offers longer survival in difficult disease Jun 04, 2019
'Unprecedented' Survival Benefit Vanishes in Confirmatory Cancer Trial Over $500 million in sales for drug with possibly no benefit Jun 03, 2019
